Hexaell Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hexaell Biotech - overview
Established
2015
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Established in 2015 and based in Shanghai, China, Hexaell Biotech Co. , Ltd. , trading as Hexaell Biotech, operates as a biotechnology company that focuses on severe liver diseases and cell therapy. It has production lines and R&D centers in Jiading and Zhangjiang, Shanghai.
In September 2025, the company closed a round of venture funding from Qihang Capital. The company focuses on severe liver diseases and cell therapy. It uses hepatocyte transdifferentiation and expansion technology to build the HepaCure bioartificial liver support system, which is an in vitro liver function support system suitable for patients with liver failure and postoperative rehabilitation of patients with liver resection. Hexaell Biotech also uses primary hepatocyte in vitro expansion technology to build proliferating human primary hepatocytes ProliHH, which can be used for hepatocyte transplantation to treat genetic metabolic liver diseases, and drug screening and other R&D services.
The company generates revenue by providing bioartificial liver products and hepatocyte transplant products, as well as developing cell therapy technologies.
Current Investors
Hyfinity Investments, Green Pine Capital Partners, Hengxu Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.hexaell.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.